all our money??? You must know something that is not reflected in the current stock price...
IMGN is taking far too long to determine max dose and optimal dosing schedules. They need a new leader, DJ has lost credibility. Hit the road Dan, you have done well financially and the shareholders have not and demand change!
agreed, for biotech the presentations are usually fluff and the meat is always in the Q&A. As another poster pointed out stability for a small molecule should not be an issue. Stability was not a problem for ARNA's 5h2c drug Belviq.
Puma's trial results in BC were very weak and the company is still valued at almost 2x IMGN. Tykerb did not enhance Herceptin. News in FierceBiotech.
Interesting, I have a new, local idea for him...
y'all got your answers, Dan P is out...finally. Good luck with a turn around, or sale. The IMGN shareholders are hoping our failed leader also named Dan will be out ASAP.
CRIS shareholders finally removed/replaced their weak, greedy, do-nothing CEO. At least they had a succession plan. IMGN has no one ready to be CEO. They do have Howard Pien, on the Board. Some may not know that Howard stepped in as interim CEO at Medarex, turned the company around and then sold it to BMS. Some would say they sold too low, or soon, but they price of the stock more than doubled from the time he took over (my recollection).
I would prefer an auction to a secret, sweetheart, insider deal. BMS seems to be focused on immunotherapy, so maybe they would not want to acquire IMGN, or maybe they would consider ADC's a diversification decision. They do have experienced oncology development pros on board. Sanofi seems to be a potential acquirer if the economics of the partnerships are better than Roche/Kadcyla. Shorts may just force the hand of the BOD if they keep pressing.
From what I read, the Sanofi/IMGN trial results looked similar in efficacy with more CR's and potentially superior safety results compared to the SGEN drug. Also why would IMGN have to fund development of 3419, I assume that would be Sanofi's responsibility no? People probably assume this is another 3-5% rev deal and not material for IMGN. Also, the internal pipeline progress is very slow. IMGN should face facts, their sole strength and value generator is John Lambert's drug discovery and technology team. They can't develop drugs, or even optimize dosing. They need to get rid of all phase II development, get rid of most of Bus Dev, get rid of IR and Junius and either sell the company, or change the model.
Don't know who is selling, but I think Dan Junius and the lost year of development is why. Also, with all of the nes focus on immunotherapy, ADC's are getting ignored. ADC"s are being treated like old technology. Immunotherapy is somewhat unproven, so all of this excitement seems overdone.
IMGN is a value biotech now, so who knows when this situation will turn around. Shareholders are getting tired of waiting for IMGN to do something to create value. I am sure I'm not the only one telling the BOD they need to stop the madness and sell the company, or get rid of DJ and hire someone with a proven track record of success in biotech turnarounds, or value generation. Shareholders must keep up the pressure.
IMGN is trading well below the value available in an acquisition. IMGN's CEO has been abusing the shareholders for years doing nothing to enhance shareholder value while taking lavish options awards and selling stock every time the stock price goes up. DJ and the BOD never buy stock, they only sell. DJ must go and the company needs to be sold to the highest bidder. Who will start the bidding, Roche, Sanofi, or an activist shareholder/owner? Shareholders need to stand up and demand a change in direction!
no US investors are interested in Eisai stock, it's not liquid and the price would tank if ARNA investors tried to liquidate.
IMGN investors have been saying that for years, "we know it works", "we hope we live long enough"... I noticed yesterday that J&J is now leading development for GVAX, a good product run by weak management. CEGE"s professor CEO Steve Sherwin ran the company into the ground (poor trial design, bad decisions, poor cash control) before the product was proven to work. Let's hope the IMGN BOD does their job and gets IMGN's technology into capable executive hands, so it can flourish and so shareholders can finally earn a return and before John Lambert retires. He and the shareholders deserve better!
come on in the water looks fine, you go first. OREX = VVUS, 0+0=0 Bel + Phen = winner. Any questions?
Nobody is interested in paying up for VVUS, or Q, they are desperate, trapped and want out. Same future for OREX. Belviq + phen (as needed) is the future. Get on board before it's too late (IMO).
They are not going to buy the company, they just want out of their losing investment. Not sure this is a positive for ARNA, probably a non-event other than it signals VVUS is failing. Why are they failing, bad product, weak market for Obesity drugs, or both, that's the question.
In biotech anything can happen and shorts usually have far more information than the smartest retail owner. A large short interest makes me nervous.
IMGN partner did another huge deal with BMS. Looks like John Lambert hooked IMGN up with a winner back in Jan, before BMS. Maybe BMS will buy both. IMGN is beaten down and set up for a low $ bid. IMO.